Lunit develops AI-powered diagnostics and a modular platform designed to connect imaging, pathology, and biomarker insights across the cancer care pathway. The company's solutions aim to improve early detection and treatment outcomes by transforming complex clinical data into actionable insights for healthcare providers and biopharma organisations.
Headquartered in Seoul, Lunit operates offices across multiple continents and partners with hospitals, healthcare providers, and biopharma leaders globally. The company's clinically validated solutions serve a range of stakeholders in cancer diagnostics and precision oncology, from screening through treatment planning.
The organisation is structured around three stated values: responsible autonomy, global collaboration, and continuous learning. Its workforce spans multiple continents and brings diverse expertise to the challenge of advancing cancer care through artificial intelligence.